BETA


2023/2156(DEC) 2022 discharge: European Medicines Agency (EMA)

Progress: Procedure completed, awaiting publication in Official Journal

RoleCommitteeRapporteurShadows
Lead CONT SARVAMAA Petri (icon: EPP EPP) RÓNAI Sándor (icon: S&D S&D), CSEH Katalin (icon: Renew Renew), EICKHOUT Bas (icon: Verts/ALE Verts/ALE), KUHS Joachim (icon: ID ID), CZARNECKI Ryszard (icon: ECR ECR), OMARJEE Younous (icon: GUE/NGL GUE/NGL)
Committee Opinion ENVI CANFIN Pascal (icon: Renew Renew) Tiemo WÖLKEN (icon: S&D S&D), Alexandr VONDRA (icon: ECR ECR), Jessica POLFJÄRD (icon: PPE PPE)
Lead committee dossier:

Events

2024/04/11
   EP - Decision by Parliament
Details

The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.

Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.

Agency’s financial statements

The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.

Budgetary and financial management

Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.

The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.

Other observations

Parliament also made a series of observations concerning performance, staff policy and digitalisation.

In particular, it noted that:

- the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;

- on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;

- other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;

- adequate Union funding should be allocated to the Agency to carry out all of its activities;

- 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;

- the Agency should be more proactive regarding digitalisation;

- on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);

- the lack of gender balances and geographical balance should be addressed;

- in order to increase cybersecurity, the Agency adopted the Information Security Strategy.

Documents
2024/04/10
   EP - Debate in Parliament
2024/03/19
   EP - Committee report tabled for plenary, single reading
Documents
2024/03/19
   EP - Committee report tabled for plenary
Documents
2024/03/12
   CSL - Supplementary non-legislative basic document
Documents
2024/03/04
   EP - Vote in committee
2024/02/12
   EP - Committee opinion
Documents
2024/02/09
   EP - Amendments tabled in committee
Documents
2024/01/16
   EP - Committee draft report
Documents
2023/10/26
   CofA - Court of Auditors: opinion, report
2023/09/12
   EP - Committee referral announced in Parliament
2023/09/11
   EP - CANFIN Pascal (Renew) appointed as rapporteur in ENVI
2023/06/28
   EC - Non-legislative basic document
2023/06/28
   EC - Non-legislative basic document published
2023/06/14
   EP - SARVAMAA Petri (EPP) appointed as rapporteur in CONT

Documents

Votes

A9-0133/2024 – Petri Sarvamaa – After § 2 – Am 1 #

2024/04/11 Outcome: -: 345, +: 225, 0: 32
HU PL FR IT CY HR LT CZ BE LU IE DE FI EL LV MT SI SK DK EE BG RO AT SE NL PT ES
Total
16
49
67
62
2
5
10
20
21
6
12
84
13
15
8
4
7
13
13
6
13
20
16
21
25
21
53
icon: Verts/ALE Verts/ALE
62

Poland Verts/ALE

For (1)

1

Italy Verts/ALE

3

Lithuania Verts/ALE

2

Czechia Verts/ALE

3

Belgium Verts/ALE

3

Luxembourg Verts/ALE

For (1)

1

Ireland Verts/ALE

1

Finland Verts/ALE

3

Greece Verts/ALE

For (1)

1

Denmark Verts/ALE

2

Austria Verts/ALE

For (1)

1

Sweden Verts/ALE

3

Netherlands Verts/ALE

2

Portugal Verts/ALE

1

Spain Verts/ALE

3
icon: ECR ECR
62

France ECR

For (1)

1

Croatia ECR

1

Lithuania ECR

1

Germany ECR

1

Finland ECR

2

Greece ECR

1

Latvia ECR

For (1)

1

Slovakia ECR

Abstain (1)

1

Bulgaria ECR

2

Sweden ECR

For (1)

3
icon: ID ID
49

Czechia ID

For (1)

1

Denmark ID

Abstain (1)

1

Austria ID

Abstain (2)

2
icon: The Left The Left
32

Cyprus The Left

1

Czechia The Left

1

Belgium The Left

For (1)

1

Finland The Left

For (1)

1

Greece The Left

1

Denmark The Left

1

Sweden The Left

Abstain (1)

1

Netherlands The Left

Against (1)

1

Portugal The Left

4
icon: NI NI
37

Belgium NI

Against (1)

1

Germany NI

2

Latvia NI

1

Romania NI

For (1)

1

Netherlands NI

Against (1)

1
icon: Renew Renew
93

Hungary Renew

2

Poland Renew

1

Italy Renew

Against (2)

3

Lithuania Renew

Against (1)

1

Belgium Renew

For (1)

4

Luxembourg Renew

2

Ireland Renew

2

Finland Renew

2

Greece Renew

Against (1)

1

Latvia Renew

Against (1)

1

Slovenia Renew

2

Slovakia Renew

3

Estonia Renew

3

Bulgaria Renew

For (1)

3

Austria Renew

Against (1)

1

Sweden Renew

3
icon: S&D S&D
121
4

Croatia S&D

3

Lithuania S&D

For (1)

2

Czechia S&D

Against (1)

1

Belgium S&D

Against (1)

2

Luxembourg S&D

For (1)

1

Finland S&D

2

Greece S&D

Against (1)

1

Latvia S&D

2

Slovenia S&D

Against (1)

1

Slovakia S&D

For (1)

1

Denmark S&D

2

Estonia S&D

2

Bulgaria S&D

2
icon: PPE PPE
146

Hungary PPE

Abstain (1)

1

Cyprus PPE

Against (1)

1

Croatia PPE

Against (1)

1

Belgium PPE

Abstain (1)

4

Luxembourg PPE

2

Latvia PPE

3

Malta PPE

Against (1)

1

Slovenia PPE

For (1)

4

Denmark PPE

Against (1)

1

Estonia PPE

Against (1)

1

A9-0133/2024 – Petri Sarvamaa – After § 5 – Am 2 #

2024/04/11 Outcome: -: 485, +: 96, 0: 17
HU PL HR CY MT EE SI LT LU BG SK LV FI IE EL DK RO NL CZ AT BE SE PT FR ES IT DE
Total
17
45
5
3
4
7
7
10
6
13
13
7
12
12
15
13
19
25
20
18
21
21
21
64
52
62
86
icon: ECR ECR
55

Croatia ECR

1

Lithuania ECR

1

Bulgaria ECR

2

Slovakia ECR

Against (1)

1

Finland ECR

Abstain (1)

2

Greece ECR

1

Netherlands ECR

Against (1)

Abstain (1)

5

Sweden ECR

For (1)

3

Germany ECR

1
icon: ID ID
49

Estonia ID

For (1)

1

Denmark ID

Abstain (1)

1

Czechia ID

For (1)

1

Austria ID

Abstain (2)

2
icon: NI NI
38

Latvia NI

Against (1)

1

Romania NI

Against (1)

1

Netherlands NI

1

Belgium NI

Against (1)

1

Germany NI

For (1)

Against (1)

2
icon: The Left The Left
31

Cyprus The Left

Against (1)

1

Ireland The Left

4

Greece The Left

1

Denmark The Left

Against (1)

1

Netherlands The Left

Against (1)

1

Czechia The Left

1

Belgium The Left

Against (1)

1

Sweden The Left

Against (1)

1
icon: Verts/ALE Verts/ALE
65

Poland Verts/ALE

Against (1)

1

Lithuania Verts/ALE

Against (1)

2

Luxembourg Verts/ALE

Against (1)

1

Finland Verts/ALE

For (1)

3

Ireland Verts/ALE

1

Greece Verts/ALE

Against (1)

1

Denmark Verts/ALE

2

Netherlands Verts/ALE

Against (1)

2

Czechia Verts/ALE

3

Austria Verts/ALE

3

Belgium Verts/ALE

3

Sweden Verts/ALE

3

Portugal Verts/ALE

Against (1)

1

Spain Verts/ALE

3

Italy Verts/ALE

Abstain (1)

3
icon: Renew Renew
91

Hungary Renew

2

Poland Renew

1

Estonia Renew

3

Slovenia Renew

2

Lithuania Renew

Against (1)

1

Luxembourg Renew

2

Bulgaria Renew

For (1)

3

Slovakia Renew

3

Latvia Renew

Against (1)

1

Finland Renew

2

Ireland Renew

2

Greece Renew

Against (1)

1

Austria Renew

Against (1)

1

Sweden Renew

3

Italy Renew

3
icon: S&D S&D
122

Cyprus S&D

Against (1)

1

Estonia S&D

2

Slovenia S&D

Against (1)

1

Lithuania S&D

2

Luxembourg S&D

Against (1)

1

Bulgaria S&D

2

Slovakia S&D

For (1)

1

Latvia S&D

2

Finland S&D

2

Greece S&D

Against (1)

1

Denmark S&D

2

Czechia S&D

Against (1)

1

Belgium S&D

2
icon: PPE PPE
147

Hungary PPE

1

Croatia PPE

Against (1)

1

Cyprus PPE

Against (1)

1

Malta PPE

Against (1)

1

Estonia PPE

Against (1)

1

Slovenia PPE

For (1)

4

Luxembourg PPE

2

Latvia PPE

3

Denmark PPE

Against (1)

1

A9-0133/2024 – Petri Sarvamaa – After § 7 – Am 3 #

2024/04/11 Outcome: -: 485, +: 78, 0: 34
PL HR CY MT LV HU SI LT LU EE SK CZ BG EL FI IE DK NL AT RO SE PT BE FR IT ES DE
Total
49
5
3
4
7
16
7
10
6
6
13
18
12
15
13
12
13
26
18
19
21
21
21
66
60
52
84
icon: ECR ECR
60

Croatia ECR

1

Latvia ECR

For (1)

1

Lithuania ECR

1

Slovakia ECR

Against (1)

1

Bulgaria ECR

For (1)

1

Greece ECR

1

Finland ECR

Abstain (1)

2

Sweden ECR

For (1)

3

Germany ECR

1
icon: ID ID
49

Czechia ID

For (1)

1

Denmark ID

Abstain (1)

1

Austria ID

Abstain (2)

2

Belgium ID

Against (1)

3
icon: NI NI
36

Latvia NI

Against (1)

1

Netherlands NI

1

Belgium NI

Against (1)

1

Germany NI

For (1)

Against (1)

2
icon: The Left The Left
32

Cyprus The Left

Against (1)

1

Czechia The Left

1

Greece The Left

1

Finland The Left

Against (1)

1

Ireland The Left

4

Denmark The Left

Against (1)

1

Netherlands The Left

Against (1)

1

Sweden The Left

Against (1)

1

Belgium The Left

Against (1)

1

France The Left

Abstain (1)

5
icon: Verts/ALE Verts/ALE
65

Poland Verts/ALE

Against (1)

1

Lithuania Verts/ALE

Against (1)

2

Luxembourg Verts/ALE

Against (1)

1

Czechia Verts/ALE

3

Greece Verts/ALE

Against (1)

1

Finland Verts/ALE

3

Ireland Verts/ALE

Against (1)

1

Denmark Verts/ALE

2

Netherlands Verts/ALE

2

Austria Verts/ALE

3

Sweden Verts/ALE

3

Portugal Verts/ALE

Against (1)

1

Belgium Verts/ALE

3

Italy Verts/ALE

Against (1)

Abstain (1)

3

Spain Verts/ALE

3
icon: Renew Renew
92

Poland Renew

1

Latvia Renew

Against (1)

1

Hungary Renew

2

Slovenia Renew

2

Lithuania Renew

Against (1)

1

Luxembourg Renew

2

Estonia Renew

3

Slovakia Renew

3

Czechia Renew

Against (1)

4

Bulgaria Renew

3

Greece Renew

Against (1)

1

Finland Renew

2

Ireland Renew

2

Austria Renew

Against (1)

1

Sweden Renew

3

Italy Renew

3
icon: S&D S&D
119

Cyprus S&D

Against (1)

1

Latvia S&D

Against (1)

1

Hungary S&D

3

Slovenia S&D

Against (1)

1

Lithuania S&D

2

Luxembourg S&D

Against (1)

1

Estonia S&D

2

Slovakia S&D

Against (1)

1

Czechia S&D

Against (1)

1

Bulgaria S&D

2

Greece S&D

Against (1)

1

Finland S&D

2

Denmark S&D

2

Belgium S&D

2
icon: PPE PPE
144

Croatia PPE

Against (1)

1

Cyprus PPE

Against (1)

1

Malta PPE

Against (1)

1

Latvia PPE

3

Hungary PPE

Against (1)

1

Slovenia PPE

For (1)

4

Luxembourg PPE

2

Estonia PPE

Against (1)

1

Denmark PPE

Against (1)

1

A9-0133/2024 – Petri Sarvamaa – After § 7 – Am 4 #

2024/04/11 Outcome: -: 454, +: 94, 0: 53
PL HR CY LT MT EE SI LV HU LU SK BG FI CZ BE EL IE DK AT RO IT SE NL PT FR ES DE
Total
49
5
3
8
4
7
7
8
17
6
13
13
12
20
21
13
11
13
17
20
59
21
26
21
67
54
86
icon: ECR ECR
61

Croatia ECR

1

Lithuania ECR

1

Latvia ECR

For (1)

1

Slovakia ECR

Abstain (1)

1

Bulgaria ECR

2

Finland ECR

2

Belgium ECR

Against (1)

3

Greece ECR

Against (1)

1

Sweden ECR

For (1)

3

Netherlands ECR

Against (1)

Abstain (1)

5

France ECR

For (1)

1

Germany ECR

1
icon: ID ID
50

Estonia ID

For (1)

1

Czechia ID

For (1)

1

Denmark ID

Abstain (1)

1

Austria ID

Abstain (2)

2
icon: NI NI
35

Latvia NI

Against (1)

1

Belgium NI

Against (1)

1

Romania NI

For (1)

1

Netherlands NI

1

Germany NI

For (1)

Against (1)

2
icon: The Left The Left
31

Cyprus The Left

Against (1)

1

Czechia The Left

1

Belgium The Left

Abstain (1)

1

Greece The Left

1

Ireland The Left

3

Denmark The Left

Against (1)

1

Sweden The Left

Against (1)

1

Netherlands The Left

Against (1)

1
icon: Verts/ALE Verts/ALE
65

Poland Verts/ALE

Against (1)

1

Lithuania Verts/ALE

Against (1)

2

Luxembourg Verts/ALE

Against (1)

1

Finland Verts/ALE

3

Czechia Verts/ALE

3

Belgium Verts/ALE

3

Greece Verts/ALE

Against (1)

1

Ireland Verts/ALE

Against (1)

1

Denmark Verts/ALE

2

Austria Verts/ALE

3

Italy Verts/ALE

Against (1)

Abstain (1)

3

Sweden Verts/ALE

3

Netherlands Verts/ALE

2

Portugal Verts/ALE

Against (1)

1

Spain Verts/ALE

3
icon: Renew Renew
93

Poland Renew

1

Lithuania Renew

Against (1)

1

Estonia Renew

3

Slovenia Renew

2

Latvia Renew

Against (1)

1

Hungary Renew

2

Luxembourg Renew

2

Slovakia Renew

3

Bulgaria Renew

3

Finland Renew

2

Greece Renew

Against (1)

1

Ireland Renew

2

Austria Renew

Against (1)

1

Italy Renew

3

Sweden Renew

3
icon: S&D S&D
121

Cyprus S&D

Against (1)

1

Lithuania S&D

2

Estonia S&D

2

Slovenia S&D

Against (1)

1

Latvia S&D

2

Luxembourg S&D

Against (1)

1

Slovakia S&D

Against (1)

1

Bulgaria S&D

2

Finland S&D

2

Czechia S&D

Against (1)

1

Belgium S&D

2

Greece S&D

Against (1)

1

Denmark S&D

2
icon: PPE PPE
145

Croatia PPE

Against (1)

1

Cyprus PPE

Against (1)

1

Lithuania PPE

2

Malta PPE

Against (1)

1

Estonia PPE

Against (1)

1

Slovenia PPE

For (1)

4

Latvia PPE

3

Hungary PPE

Against (1)

1

Luxembourg PPE

2

Belgium PPE

Abstain (1)

4

Denmark PPE

Against (1)

1

A9-0133/2024 – Petri Sarvamaa – Motion for a resolution (as a whole) #

2024/04/11 Outcome: +: 528, -: 71, 0: 4
DE PL ES FR IT PT NL RO CZ HU SE AT BE BG IE DK FI SK LT LV EL SI LU HR EE MT CY
Total
85
49
52
67
61
21
26
20
20
16
21
18
21
13
11
13
12
13
10
7
15
7
6
5
7
4
3
icon: PPE PPE
147

Hungary PPE

1

Denmark PPE

For (1)

1

Luxembourg PPE

2

Croatia PPE

For (1)

1

Estonia PPE

For (1)

1

Malta PPE

For (1)

1

Cyprus PPE

For (1)

1
icon: S&D S&D
118

Czechia S&D

For (1)

1

Belgium S&D

2

Bulgaria S&D

2

Denmark S&D

2

Slovakia S&D

For (1)

1

Lithuania S&D

2

Latvia S&D

For (1)

1

Greece S&D

1

Slovenia S&D

For (1)

1

Luxembourg S&D

For (1)

1

Estonia S&D

2

Cyprus S&D

1
icon: Renew Renew
93

Poland Renew

1

Hungary Renew

2
3

Austria Renew

For (1)

1

Ireland Renew

2

Finland Renew

2

Slovakia Renew

3

Lithuania Renew

1

Latvia Renew

For (1)

1

Greece Renew

1

Slovenia Renew

2

Luxembourg Renew

2

Estonia Renew

3
icon: Verts/ALE Verts/ALE
64

Poland Verts/ALE

For (1)

1

Spain Verts/ALE

3

Italy Verts/ALE

3

Portugal Verts/ALE

1

Netherlands Verts/ALE

2

Czechia Verts/ALE

3

Sweden Verts/ALE

3

Austria Verts/ALE

3

Belgium Verts/ALE

3

Ireland Verts/ALE

1

Denmark Verts/ALE

2

Finland Verts/ALE

3

Lithuania Verts/ALE

For (1)

Abstain (1)

2

Greece Verts/ALE

For (1)

1

Luxembourg Verts/ALE

For (1)

1
icon: ECR ECR
62

Germany ECR

1

France ECR

For (1)

1

Sweden ECR

3

Bulgaria ECR

2

Finland ECR

2

Slovakia ECR

For (1)

1

Lithuania ECR

1

Latvia ECR

For (1)

1

Greece ECR

Against (1)

1

Croatia ECR

1
icon: The Left The Left
31

Netherlands The Left

For (1)

1

Czechia The Left

Against (1)

1

Sweden The Left

For (1)

1

Belgium The Left

Against (1)

1

Denmark The Left

1

Greece The Left

1

Cyprus The Left

1
icon: NI NI
38

Germany NI

2

Netherlands NI

Against (1)

1

Romania NI

For (1)

1

Belgium NI

For (1)

1

Latvia NI

1
icon: ID ID
50

Czechia ID

Against (1)

1

Austria ID

Against (2)

2

Denmark ID

Against (1)

1

Estonia ID

Against (1)

1
AmendmentsDossier
20 2023/2156(DEC)
2023/12/04 ENVI 20 amendments...
source: 757.131

History

(these mark the time of scraping, not the official date of the change)

docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/5/summary
  • The European Parliament decided to grant discharge to the Executive Director of the European Medicines Agency (EMA) for the financial year 2022 and to approve the closure of the accounts for that year.
  • Noting that the Court of Auditors has stated that it has obtained reasonable assurance that the Agency's annual accounts for the financial year 2022 are reliable and that the underlying transactions are legal and regular, Parliament adopted, by 528 votes to 71 with 4 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations set out in the resolution on the performance, financial management and control of EU agencies.
  • Agency’s financial statements
  • The Agency's final budget for the year 2022 was EUR 421 815 000 , representing an increase of 11.23 % compared to 2021. The Agency is a fee-funded agency, with approximately 88 % of its 2022 revenue stemming from fees derived from the evaluation of medicines and other business-related activities, and 12 % stemming from the Union budget and miscellaneous income.
  • Budgetary and financial management
  • Budget monitoring efforts during the financial year 2022 resulted in a budget implementation rate of current year commitment appropriations of 96.80 %, representing a decrease of 0.42 % compared to 2021. Payment appropriations execution rate was 71.48 %, representing a decrease of 0.88 % compared to 2021.
  • The resolution recalled that potential liabilities arising, until 2039, from the lease on the Agency’s former office premises in London remain an ongoing issue. On 31 December 2022, the total estimated outstanding rent, associated service charges and landlord insurance to be paid by the Agency up to the end of the lease term was EUR 366 million, that is approximately EUR 23 million annually. In 2019, the Agency reached an agreement with its landlord, and sublet its former premises to a subtenant with effect from July 2019. The term of the sublease lasts until the Agency´s lease expires in June 2039 and, since the Agency remains a party to the head lease, it could be held liable for the entire amount remaining payable under the contractual obligations of the head lease, if the subtenant fails to meet its obligations.
  • Other observations
  • Parliament also made a series of observations concerning performance, staff policy and digitalisation.
  • In particular, it noted that:
  • - the Agency reported on 41 performance indicators, estimating an implementation rate of 92.60 %;
  • - on 1 March 2022, the Agency’s mandate was extended reinforcing its role in crisis preparedness and management of medicinal products and medical devices;
  • - other key achievements in 2022 include the approval of two new vaccines and two COVID-19 treatments, the ETF recommended the temporary use of the US-approved monkeypox vaccine Jynneos for Monkeypox to support vaccination efforts by national EU authorities, alongside an extension of the use of Imvanex to also protect adults from monkeypox;
  • - adequate Union funding should be allocated to the Agency to carry out all of its activities;
  • - 52 % of applicants who have been granted a positive opinion for their medicinal product have received scientific advice or protocol assistance from the Agency during the development phase of their product, with this figure rising to 78 % for applicants for medicinal products with new active substances;
  • - the Agency should be more proactive regarding digitalisation;
  • - on 31 December 2022, the establishment plan was 99.39 % implemented, with 658 temporary agents appointed out of 662 temporary agents authorised under the Union budget (compared to 657 authorised posts in 2021);
  • - the lack of gender balances and geographical balance should be addressed;
  • - in order to increase cybersecurity, the Agency adopted the Information Security Strategy.
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/4
date
2024-04-10T00:00:00
type
Debate in Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/CRE-9-2024-04-10-TOC_EN.html title: Debate in Parliament
events/5
date
2024-04-11T00:00:00
type
Decision by Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
forecasts
  • date: 2024-04-10T00:00:00 title: Indicative plenary sitting date
procedure/stage_reached
Old
Awaiting Parliament's vote
New
Procedure completed, awaiting publication in Official Journal
docs/7
date
2024-04-11T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
type
Text adopted by Parliament, single reading
body
EP
events/4
date
2024-04-10T00:00:00
type
Debate in Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/CRE-9-2024-04-10-TOC_EN.html title: Debate in Parliament
events/5
date
2024-04-11T00:00:00
type
Decision by Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0245_EN.html title: T9-0245/2024
forecasts
  • date: 2024-04-10T00:00:00 title: Indicative plenary sitting date
procedure/stage_reached
Old
Awaiting Parliament's vote
New
Procedure completed, awaiting publication in Official Journal
events/4
date
2024-04-10T00:00:00
type
Debate in Parliament
body
EP
forecasts
  • date: 2024-04-10T00:00:00 title: Indicative plenary sitting date
events/4
date
2024-04-10T00:00:00
type
Debate in Parliament
body
EP
forecasts
  • date: 2024-04-10T00:00:00 title: Indicative plenary sitting date
events/4
date
2024-04-10T00:00:00
type
Debate in Parliament
body
EP
forecasts/0
date
2024-04-11T00:00:00
title
Vote scheduled
forecasts/0
date
2024-04-10T00:00:00
title
Indicative plenary sitting date
docs/6
date
2024-03-19T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/A-9-2024-0133_EN.html title: A9-0133/2024
type
Committee report tabled for plenary, single reading
body
EP
events/3
date
2024-03-19T00:00:00
type
Committee report tabled for plenary
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-9-2024-0133_EN.html title: A9-0133/2024
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
docs/6
date
2024-03-19T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/A-9-2024-0133_EN.html title: A9-0133/2024
type
Committee report tabled for plenary, single reading
body
EP
events/3
date
2024-03-19T00:00:00
type
Committee report tabled for plenary
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-9-2024-0133_EN.html title: A9-0133/2024
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
events/3
date
2024-03-19T00:00:00
type
Committee report tabled for plenary
body
EP
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
events/3
date
2024-03-19T00:00:00
type
Committee report tabled for plenary
body
EP
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
events/3
date
2024-03-19T00:00:00
type
Committee report tabled for plenary
body
EP
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
events/3
date
2024-03-19T00:00:00
type
Committee report tabled for plenary
body
EP
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
events/3
date
2024-03-19T00:00:00
type
Committee report tabled for plenary
body
EP
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
events/3
date
2024-03-19T00:00:00
type
Committee report tabled for plenary
body
EP
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
docs/5
date
2024-03-12T00:00:00
docs
title: 06180/2024
type
Supplementary non-legislative basic document
body
CSL
events/2
date
2024-03-04T00:00:00
type
Vote in committee
body
EP
forecasts
  • date: 2024-04-10T00:00:00 title: Indicative plenary sitting date
docs/3
date
2024-02-09T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/CONT-AM-757226_EN.html title: PE757.226
type
Amendments tabled in committee
body
EP
docs/3/date
Old
2024-02-06T00:00:00
New
2024-02-12T00:00:00
docs/3/date
Old
2024-01-25T00:00:00
New
2024-02-06T00:00:00
docs/3
date
2024-01-25T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/ENVI-AD-754678_EN.html title: PE754.678
committee
ENVI
type
Committee opinion
body
EP
docs/2
date
2024-01-16T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/CONT-PR-753524_EN.html title: PE753.524
type
Committee draft report
body
EP
docs/1
date
2023-10-26T00:00:00
docs
type
Court of Auditors: opinion, report
body
CofA
commission
  • body: EC dg: Budget commissioner: HAHN Johannes
events/1
date
2023-09-12T00:00:00
type
Committee referral announced in Parliament
body
EP
procedure/dossier_of_the_committee